Topics:

Merck and Idera to develop TLR9 agonists for treatment of cancer

Merck and Idera to develop TLR9 agonists for treatment of cancer

DARMSTADT, Germany—Merck KGaA has entered into a worldwide licensing and collaboration agreement, on behalf of its Merck Serono division, with Idera Pharmaceuticals of Cambridge, Massachusetts, for the research, development, and commercialization of Idera's toll-like receptor 9 (TLR9) agonists IMO-2055 and IMO-2125, and any follow-on TLR9 agonists identified through the collaboration.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.